Ivone U S Leong, Claudia P Cabrera, Valentina Cipriani, Paul J Ross, Richard M Turner, Alex Stuckey, Sonali Sanghvi, Dorota Pasko, Loukas Moutsianas, Christopher A Odhams, Greg S Elgar, Georgia Chan, Adam Giess, Susan Walker, Rebecca E Foulger, Eleanor M Williams, Louise C Daugherty, Antonio Rueda-Martin, Daniel J Rhodes, Olivia Niblock, Alexandra Pickard, Lauren Marks, Sarah E A Leigh, Matthew J Welland, Marta Bleda, Catherine Snow, Zandra Deans, Nirupa Murugaesu, Richard H Scott, Michael R Barnes, Matthew A Brown, Augusto Rendon, Sue Hill, Alona Sosinsky, Mark J Caulfield, Ellen M McDonagh
{"title":"结合全基因组测序和医疗记录为临床实践提供信息的 \"十万基因组计划 \"癌症患者大规模药物基因组学分析。","authors":"Ivone U S Leong, Claudia P Cabrera, Valentina Cipriani, Paul J Ross, Richard M Turner, Alex Stuckey, Sonali Sanghvi, Dorota Pasko, Loukas Moutsianas, Christopher A Odhams, Greg S Elgar, Georgia Chan, Adam Giess, Susan Walker, Rebecca E Foulger, Eleanor M Williams, Louise C Daugherty, Antonio Rueda-Martin, Daniel J Rhodes, Olivia Niblock, Alexandra Pickard, Lauren Marks, Sarah E A Leigh, Matthew J Welland, Marta Bleda, Catherine Snow, Zandra Deans, Nirupa Murugaesu, Richard H Scott, Michael R Barnes, Matthew A Brown, Augusto Rendon, Sue Hill, Alona Sosinsky, Mark J Caulfield, Ellen M McDonagh","doi":"10.1200/JCO.23.02761","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>As part of the 100,000 Genomes Project, we set out to assess the potential viability and clinical impact of reporting genetic variants associated with drug-induced toxicity for patients with cancer recruited for whole-genome sequencing (WGS) as part of a genomic medicine service.</p><p><strong>Methods: </strong>Germline WGS from 76,805 participants was analyzed for pharmacogenetic (PGx) variants in four genes (<i>DPYD</i>, <i>NUDT15</i>, <i>TPMT</i>, <i>UGT1A1</i>) associated with toxicity induced by five drugs used in cancer treatment (capecitabine, fluorouracil, mercaptopurine, thioguanine, irinotecan). Linking genomic data with prescribing and hospital incidence records, a phenome-wide association study (PheWAS) was performed to identify whether phenotypes indicative of adverse drug reactions (ADRs) were enriched in drug-exposed individuals with the relevant PGx variants. In a subset of 7,081 patients with cancer, <i>DPYD</i> variants were reported back to clinicians and outcomes were collected.</p><p><strong>Results: </strong>We identified clinically relevant PGx variants across the four genes in 62.7% of participants in our cohort. Extending this to annual prescription numbers in England for the drugs affected by these PGx variants, approximately 14,540 patients per year could potentially benefit from a reduced dose or alternative drug to reduce the risk of ADRs. Validating PGx associations in a real-world data set, we found a significant association between PGx variants in <i>DPYD</i> and toxicity-related phenotypes in patients treated with capecitabine or fluorouracil. Reported <i>DPYD</i> variants were deemed informative for clinical decision making in a majority of cases.</p><p><strong>Conclusion: </strong>Reporting PGx variants from germline WGS relevant to patients with cancer alongside primary findings related to their cancer can be clinically informative, informing prescribing to reduce the risk of ADRs. Extending the range of actionable variants to those found in patients of non-European ancestry is important and will extend the potential clinical impact.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2302761"},"PeriodicalIF":42.1000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice.\",\"authors\":\"Ivone U S Leong, Claudia P Cabrera, Valentina Cipriani, Paul J Ross, Richard M Turner, Alex Stuckey, Sonali Sanghvi, Dorota Pasko, Loukas Moutsianas, Christopher A Odhams, Greg S Elgar, Georgia Chan, Adam Giess, Susan Walker, Rebecca E Foulger, Eleanor M Williams, Louise C Daugherty, Antonio Rueda-Martin, Daniel J Rhodes, Olivia Niblock, Alexandra Pickard, Lauren Marks, Sarah E A Leigh, Matthew J Welland, Marta Bleda, Catherine Snow, Zandra Deans, Nirupa Murugaesu, Richard H Scott, Michael R Barnes, Matthew A Brown, Augusto Rendon, Sue Hill, Alona Sosinsky, Mark J Caulfield, Ellen M McDonagh\",\"doi\":\"10.1200/JCO.23.02761\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>As part of the 100,000 Genomes Project, we set out to assess the potential viability and clinical impact of reporting genetic variants associated with drug-induced toxicity for patients with cancer recruited for whole-genome sequencing (WGS) as part of a genomic medicine service.</p><p><strong>Methods: </strong>Germline WGS from 76,805 participants was analyzed for pharmacogenetic (PGx) variants in four genes (<i>DPYD</i>, <i>NUDT15</i>, <i>TPMT</i>, <i>UGT1A1</i>) associated with toxicity induced by five drugs used in cancer treatment (capecitabine, fluorouracil, mercaptopurine, thioguanine, irinotecan). Linking genomic data with prescribing and hospital incidence records, a phenome-wide association study (PheWAS) was performed to identify whether phenotypes indicative of adverse drug reactions (ADRs) were enriched in drug-exposed individuals with the relevant PGx variants. In a subset of 7,081 patients with cancer, <i>DPYD</i> variants were reported back to clinicians and outcomes were collected.</p><p><strong>Results: </strong>We identified clinically relevant PGx variants across the four genes in 62.7% of participants in our cohort. Extending this to annual prescription numbers in England for the drugs affected by these PGx variants, approximately 14,540 patients per year could potentially benefit from a reduced dose or alternative drug to reduce the risk of ADRs. Validating PGx associations in a real-world data set, we found a significant association between PGx variants in <i>DPYD</i> and toxicity-related phenotypes in patients treated with capecitabine or fluorouracil. Reported <i>DPYD</i> variants were deemed informative for clinical decision making in a majority of cases.</p><p><strong>Conclusion: </strong>Reporting PGx variants from germline WGS relevant to patients with cancer alongside primary findings related to their cancer can be clinically informative, informing prescribing to reduce the risk of ADRs. Extending the range of actionable variants to those found in patients of non-European ancestry is important and will extend the potential clinical impact.</p>\",\"PeriodicalId\":15384,\"journal\":{\"name\":\"Journal of Clinical Oncology\",\"volume\":\" \",\"pages\":\"JCO2302761\"},\"PeriodicalIF\":42.1000,\"publicationDate\":\"2024-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1200/JCO.23.02761\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/JCO.23.02761","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice.
Purpose: As part of the 100,000 Genomes Project, we set out to assess the potential viability and clinical impact of reporting genetic variants associated with drug-induced toxicity for patients with cancer recruited for whole-genome sequencing (WGS) as part of a genomic medicine service.
Methods: Germline WGS from 76,805 participants was analyzed for pharmacogenetic (PGx) variants in four genes (DPYD, NUDT15, TPMT, UGT1A1) associated with toxicity induced by five drugs used in cancer treatment (capecitabine, fluorouracil, mercaptopurine, thioguanine, irinotecan). Linking genomic data with prescribing and hospital incidence records, a phenome-wide association study (PheWAS) was performed to identify whether phenotypes indicative of adverse drug reactions (ADRs) were enriched in drug-exposed individuals with the relevant PGx variants. In a subset of 7,081 patients with cancer, DPYD variants were reported back to clinicians and outcomes were collected.
Results: We identified clinically relevant PGx variants across the four genes in 62.7% of participants in our cohort. Extending this to annual prescription numbers in England for the drugs affected by these PGx variants, approximately 14,540 patients per year could potentially benefit from a reduced dose or alternative drug to reduce the risk of ADRs. Validating PGx associations in a real-world data set, we found a significant association between PGx variants in DPYD and toxicity-related phenotypes in patients treated with capecitabine or fluorouracil. Reported DPYD variants were deemed informative for clinical decision making in a majority of cases.
Conclusion: Reporting PGx variants from germline WGS relevant to patients with cancer alongside primary findings related to their cancer can be clinically informative, informing prescribing to reduce the risk of ADRs. Extending the range of actionable variants to those found in patients of non-European ancestry is important and will extend the potential clinical impact.
期刊介绍：
The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
